IDEAYA Biosciences (IDYA) AI Stock Analysis

• Market Cap: $1.83B
• Dividend Yield: N/A
• Average Volume (3M): 1.59M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.49
• Revenue Growth: -70.07%
• EPS Growth: -67.97%
• Country: US
• Employees: 131
• Sector: Healthcare
• Sector Strength: 56
• Industry: Biotechnology
• EPS (TTM): -3.30
• Shares Outstanding: 87,537,390
• 10 Day Avg. Volume: 1,440,199
• 30 Day Avg. Volume: 1,592,927
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.87
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 226.79
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $51.75
• Price Target Upside: 147.25% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

IDEAYA Biosciences faces key financial challenges with declining revenues and net losses, impacting its overall score. The stock's bearish technical indicators further weigh down the score, despite a positive corporate event with the appointment of a new CFO. Valuation metrics remain weak due to lack of profitability, limiting investor appeal.

Positive Factors

Clinical Developments

The ability to show a benefit on event-free survival with the addition of darovasertib presents an upside case for the company.

Regulatory Advancement

FDA Breakthrough Therapy Designation for monotherapy darovasertib in neoadjuvant uveal melanoma may accelerate future FDA interactions and review processes.

Trial Expansion

The total sample size for the trial has increased to 520 due to the decision to expand the pool of plaque patients, which indicates a comprehensive approach.

Negative Factors

Financial Concerns

IDYA has an annualized cash burn of $300 million, which may concern investors regarding long-term financial sustainability.

Market Skepticism

Short interest represents 13.8% of the float, indicating a significant level of skepticism among some investors.

Regulatory Challenges

The majority of the neoadjuvant opportunity lies in the ~80% of patients scheduled for radiotherapy, which does not appear to be included in this BTD designation.

IDEAYA Biosciences Business Overview & Revenue Model

Company Description

IDEAYA Biosciences, Inc. (IDYA) is a biotechnology company dedicated to the discovery and development of precision medicine therapies targeting cancer and other genetically defined diseases. The company operates in the field of synthetic lethality, a novel approach to cancer treatment that exploits genetic vulnerabilities in cancer cells. IDEAYA's core products include a pipeline of small molecule therapeutics focused on the areas of synthetic lethality and immuno-oncology.

How the Company Makes Money

IDEAYA Biosciences generates revenue primarily through collaborative research and licensing agreements with pharmaceutical companies. These partnerships often involve upfront payments, milestone payments, and royalties from future product sales. Significant collaborations, such as with GlaxoSmithKline (GSK), contribute to its earnings by providing funding for research and development activities. Additionally, IDEAYA may earn revenue from government grants and other funding sources to support its clinical and preclinical programs.

IDEAYA Biosciences Financial Statement Overview

Summary

IDEAYA Biosciences faces significant financial challenges with declining revenues and consistent net losses. The company maintains a strong equity position, suggesting stability, but profitability and cash flow constraints pose risks. Strategic improvements are necessary for future growth.

Income Statement

The company has seen a significant decline in revenue over the past year, with a negative growth rate of 70%. Gross profit margin remains at 100% due to no cost of goods sold reported. However, high negative net profit, EBIT, and EBITDA margins reflect operational challenges and lack of profitability.

Balance Sheet

IDEAYA Biosciences maintains a strong equity base, with an equity ratio of 94%. The debt-to-equity ratio is low, indicating minimal leverage, but return on equity is negative due to net losses, highlighting profitability challenges.

Cash Flow

Operating cash flow and free cash flow are both negative, indicating cash burn from operations. However, the company has managed substantial financing activities, improving cash reserves significantly, albeit not enough to cover the free cash flow deficit.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
7.00M	23.39M	50.93M	27.94M	19.54M
	Gross Profit
7.00M	19.38M	48.83M	26.22M	-20.16M
	EBIT
-326.98M	-134.43M	-62.50M	-50.27M	-35.34M
	EBITDA
-326.98M	-130.42M	-60.40M	-48.54M	-33.96M
	Net Income Common Stockholders
-274.48M	-112.96M	-54.81M	-47.53M	-32.27M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
676.32M	525.11M	373.15M	368.06M	283.58M
	Total Assets
1.12B	649.32M	387.97M	381.35M	298.27M
	Total Debt
19.17M	2.87M	3.48M	5.18M	6.72M
	Net Debt
-65.21M	-154.15M	-65.15M	-86.86M	-65.31M
	Total Liabilities
64.94M	28.23M	387.97M	381.35M	298.27M
	Stockholders Equity
1.06B	621.09M	349.45M	301.51M	198.27M
Cash Flow		Free Cash Flow
-251.44M	-117.59M	-90.62M	-58.42M	54.97M
	Operating Cash Flow
-247.58M	-115.22M	-87.17M	-55.78M	55.46M
	Investing Cash Flow
-502.56M	-158.46M	-33.40M	-69.67M	-146.24M
	Financing Cash Flow
677.55M	362.72M	97.17M	145.45M	128.75M

IDEAYA Biosciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 20.93
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDYA, the sentiment is Neutral. The current price of 20.93 is above the 20-day moving average (MA) of 17.73, above the 50-day MA of 18.23, and below the 200-day MA of 27.51, indicating a neutral trend. The MACD of 0.74 indicates Negative momentum. The RSI at 68.80 is Neutral, neither overbought nor oversold. The STOCH value of 91.59 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IDYA.

IDEAYA Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KYMR	64 Neutral	$2.29B	―	-36.38%	―	-40.11%	-17.79%
IMCR	62 Neutral	$1.52B	―	-13.92%	―	24.19%	10.51%
CGON	52 Neutral	$2.21B	―	-19.18%	―	―	―
Sector *	52 Neutral	$5.35B	3.81	-42.57%	2.86%	17.10%	1.33%
IDYA	49 Neutral	$1.83B	―	-32.67%	―	-70.07%	-67.97%
BEAM	45 Neutral	$2.04B	―	-43.94%	―	-83.18%	-144.95%
ETNB	42 Neutral	$1.27B	―	-69.30%	―	―	-68.13%

IDEAYA Biosciences Corporate Events

IDEAYA Biosciences Announces Board Restructuring Plans

On March 28, 2025, Susan L. Kelley, M.D. notified IDEAYA Biosciences of her decision not to seek re-election to the Board of Directors at the 2025 annual meeting of stockholders. Dr. Kelley will resign from the Board at the end of her current term but will transition to an advisory role as Chair of the new Clinical Advisory Board. The company plans to reduce the Board size to seven directors after the meeting, and Dr. Kelley’s decision is not due to any disagreement with the company’s operations or policies.

IDEAYA Biosciences Appoints New Chief Financial Officer

On February 10, 2025, IDEAYA Biosciences, a company in the biotechnology sector, announced the appointment of Joshua Bleharski, Ph.D. as its new Chief Financial Officer, effective early May 2025. Dr. Bleharski brings extensive experience from J.P. Morgan, where he served as Managing Director and Global Co-Head of Biopharma, advising on capital markets and corporate strategies. This appointment is expected to strengthen IDEAYA’s leadership team, potentially enhancing its market strategies and investor relations in the biopharma industry.